AAPL297.49+3.19 (+1.08%) ▲|ABBV234.67-0.10 (-0.04%) ▼|ABT91.05+0.52 (+0.57%) ▲|ACN129.20+2.19 (+1.72%) ▲|ADBE198.64+1.21 (+0.61%) ▲|AMAT588.23+2.35 (+0.40%) ▲|AMD518.61-1.24 (-0.24%) ▼|AMGN351.39+4.38 (+1.26%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN239.89+5.78 (+2.47%) ▲|AVGO384.07+3.92 (+1.03%) ▲|AXP342.76+4.98 (+1.47%) ▲|BA220.97+4.26 (+1.97%) ▲|BAC57.53-0.39 (-0.66%) ▼|BKNG182.11+13.17 (+7.80%) ▲|BLK982.52-32.81 (-3.23%) ▼|BMY55.09-0.44 (-0.79%) ▼|BNY145.28-2.01 (-1.36%) ▼|BRK-B497.07+4.26 (+0.86%) ▲|C143.40-1.57 (-1.08%) ▼|CAT1,000.35+16.11 (+1.64%) ▲|CL92.99+1.56 (+1.71%) ▲|CMCSA22.59-0.22 (-0.94%) ▼|COF201.81+4.00 (+2.02%) ▲|COP106.94-3.04 (-2.76%) ▼|COST961.11+3.43 (+0.36%) ▲|CRM154.33+0.91 (+0.59%) ▲|CSCO120.51-0.64 (-0.53%) ▼|CVS101.46-0.12 (-0.11%) ▼|CVX171.56-4.42 (-2.51%) ▼|DE609.73+17.79 (+3.01%) ▲|DHR187.97+9.00 (+5.03%) ▲|DIS102.29-1.24 (-1.20%) ▼|DUK125.18+0.13 (+0.10%) ▲|EMR142.20-0.94 (-0.66%) ▼|FDX313.03-4.21 (-1.33%) ▼|GD346.28-4.06 (-1.16%) ▼|GE367.55+11.08 (+3.11%) ▲|GEV1,063.92+28.94 (+2.80%) ▲|GILD125.47+0.42 (+0.34%) ▲|GM79.81+0.86 (+1.09%) ▲|GOOG347.89+1.81 (+0.52%) ▲|GOOGL348.75+2.66 (+0.77%) ▲|GS1,081.98-12.46 (-1.14%) ▼|HD340.26+15.81 (+4.87%) ▲|HON227.06+4.69 (+2.11%) ▲|IBM262.50-2.44 (-0.92%) ▼|INTC132.90+0.62 (+0.47%) ▲|INTU268.42+10.37 (+4.02%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ240.48+1.40 (+0.59%) ▲|JPM333.09-1.06 (-0.32%) ▼|KO81.24+0.93 (+1.15%) ▲|LIN521.77+9.51 (+1.86%) ▲|LLY1,109.80+2.72 (+0.25%) ▲|LMT493.50-10.17 (-2.02%) ▼|LOW220.88+7.34 (+3.44%) ▲|LRCX368.81-2.52 (-0.68%) ▼|MA493.69+5.62 (+1.15%) ▲|MCD274.21+2.55 (+0.94%) ▲|MDLZ62.15+1.09 (+1.79%) ▲|MDT80.65+0.02 (+0.02%) ▲|META560.77-1.43 (-0.25%) ▼|MMM167.73+5.89 (+3.64%) ▲|MO72.05+0.44 (+0.61%) ▲|MRK120.85+1.25 (+1.04%) ▲|MS221.35-4.69 (-2.07%) ▼|MSFT372.37-1.58 (-0.42%) ▼|MU1,037.63-14.15 (-1.34%) ▼|NEE86.79+0.36 (+0.41%) ▲|NFLX71.73-1.10 (-1.50%) ▼|NKE41.99-0.40 (-0.93%) ▼|NOW94.53-1.41 (-1.47%) ▼|NVDA199.69-0.32 (-0.16%) ▼|ORCL157.45-7.71 (-4.67%) ▼|PEP143.17+1.12 (+0.79%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG153.09+2.23 (+1.47%) ▲|PLTR113.22-3.48 (-2.98%) ▼|PM178.59-0.10 (-0.06%) ▼|QCOM196.22-7.92 (-3.88%) ▼|RTX185.84-0.55 (-0.30%) ▼|SBUX103.92+2.87 (+2.84%) ▲|SCHW91.38-1.79 (-1.92%) ▼|SO94.74-0.20 (-0.21%) ▼|SPG218.90+2.16 (+1.00%) ▲|T22.41-0.41 (-1.78%) ▼|TMO489.11+19.76 (+4.21%) ▲|TMUS182.76-1.81 (-0.98%) ▼|TSLA378.32-3.29 (-0.86%) ▼|TXN303.86-0.50 (-0.16%) ▼|UBER74.45+4.78 (+6.86%) ▲|UNH406.37-2.89 (-0.70%) ▼|UNP260.55+1.94 (+0.75%) ▲|UPS105.24-0.59 (-0.56%) ▼|USB60.02-0.03 (-0.05%) ▼|V331.70+3.22 (+0.98%) ▲|VZ45.58-1.16 (-2.47%) ▼|WFC83.89-0.24 (-0.29%) ▼|WMT119.52+0.10 (+0.08%) ▲|XOM136.44-3.29 (-2.35%) ▼|AAPL297.49+3.19 (+1.08%) ▲|ABBV234.67-0.10 (-0.04%) ▼|ABT91.05+0.52 (+0.57%) ▲|ACN129.20+2.19 (+1.72%) ▲|ADBE198.64+1.21 (+0.61%) ▲|AMAT588.23+2.35 (+0.40%) ▲|AMD518.61-1.24 (-0.24%) ▼|AMGN351.39+4.38 (+1.26%) ▲|AMT175.05-4.33 (-2.41%) ▼|AMZN239.89+5.78 (+2.47%) ▲|AVGO384.07+3.92 (+1.03%) ▲|AXP342.76+4.98 (+1.47%) ▲|BA220.97+4.26 (+1.97%) ▲|BAC57.53-0.39 (-0.66%) ▼|BKNG182.11+13.17 (+7.80%) ▲|BLK982.52-32.81 (-3.23%) ▼|BMY55.09-0.44 (-0.79%) ▼|BNY145.28-2.01 (-1.36%) ▼|BRK-B497.07+4.26 (+0.86%) ▲|C143.40-1.57 (-1.08%) ▼|CAT1,000.35+16.11 (+1.64%) ▲|CL92.99+1.56 (+1.71%) ▲|CMCSA22.59-0.22 (-0.94%) ▼|COF201.81+4.00 (+2.02%) ▲|COP106.94-3.04 (-2.76%) ▼|COST961.11+3.43 (+0.36%) ▲|CRM154.33+0.91 (+0.59%) ▲|CSCO120.51-0.64 (-0.53%) ▼|CVS101.46-0.12 (-0.11%) ▼|CVX171.56-4.42 (-2.51%) ▼|DE609.73+17.79 (+3.01%) ▲|DHR187.97+9.00 (+5.03%) ▲|DIS102.29-1.24 (-1.20%) ▼|DUK125.18+0.13 (+0.10%) ▲|EMR142.20-0.94 (-0.66%) ▼|FDX313.03-4.21 (-1.33%) ▼|GD346.28-4.06 (-1.16%) ▼|GE367.55+11.08 (+3.11%) ▲|GEV1,063.92+28.94 (+2.80%) ▲|GILD125.47+0.42 (+0.34%) ▲|GM79.81+0.86 (+1.09%) ▲|GOOG347.89+1.81 (+0.52%) ▲|GOOGL348.75+2.66 (+0.77%) ▲|GS1,081.98-12.46 (-1.14%) ▼|HD340.26+15.81 (+4.87%) ▲|HON227.06+4.69 (+2.11%) ▲|IBM262.50-2.44 (-0.92%) ▼|INTC132.90+0.62 (+0.47%) ▲|INTU268.42+10.37 (+4.02%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ240.48+1.40 (+0.59%) ▲|JPM333.09-1.06 (-0.32%) ▼|KO81.24+0.93 (+1.15%) ▲|LIN521.77+9.51 (+1.86%) ▲|LLY1,109.80+2.72 (+0.25%) ▲|LMT493.50-10.17 (-2.02%) ▼|LOW220.88+7.34 (+3.44%) ▲|LRCX368.81-2.52 (-0.68%) ▼|MA493.69+5.62 (+1.15%) ▲|MCD274.21+2.55 (+0.94%) ▲|MDLZ62.15+1.09 (+1.79%) ▲|MDT80.65+0.02 (+0.02%) ▲|META560.77-1.43 (-0.25%) ▼|MMM167.73+5.89 (+3.64%) ▲|MO72.05+0.44 (+0.61%) ▲|MRK120.85+1.25 (+1.04%) ▲|MS221.35-4.69 (-2.07%) ▼|MSFT372.37-1.58 (-0.42%) ▼|MU1,037.63-14.15 (-1.34%) ▼|NEE86.79+0.36 (+0.41%) ▲|NFLX71.73-1.10 (-1.50%) ▼|NKE41.99-0.40 (-0.93%) ▼|NOW94.53-1.41 (-1.47%) ▼|NVDA199.69-0.32 (-0.16%) ▼|ORCL157.45-7.71 (-4.67%) ▼|PEP143.17+1.12 (+0.79%) ▲|PFE24.15-0.58 (-2.33%) ▼|PG153.09+2.23 (+1.47%) ▲|PLTR113.22-3.48 (-2.98%) ▼|PM178.59-0.10 (-0.06%) ▼|QCOM196.22-7.92 (-3.88%) ▼|RTX185.84-0.55 (-0.30%) ▼|SBUX103.92+2.87 (+2.84%) ▲|SCHW91.38-1.79 (-1.92%) ▼|SO94.74-0.20 (-0.21%) ▼|SPG218.90+2.16 (+1.00%) ▲|T22.41-0.41 (-1.78%) ▼|TMO489.11+19.76 (+4.21%) ▲|TMUS182.76-1.81 (-0.98%) ▼|TSLA378.32-3.29 (-0.86%) ▼|TXN303.86-0.50 (-0.16%) ▼|UBER74.45+4.78 (+6.86%) ▲|UNH406.37-2.89 (-0.70%) ▼|UNP260.55+1.94 (+0.75%) ▲|UPS105.24-0.59 (-0.56%) ▼|USB60.02-0.03 (-0.05%) ▼|V331.70+3.22 (+0.98%) ▲|VZ45.58-1.16 (-2.47%) ▼|WFC83.89-0.24 (-0.29%) ▼|WMT119.52+0.10 (+0.08%) ▲|XOM136.44-3.29 (-2.35%) ▼|
24.7 C
New York
Wednesday, June 24, 2026

Tag: therapies

newssourceFORcompanyinformationcontent1marketreleases

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on...

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on...

Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

Liminatus Pharma reviews digital asset treasury strategies to enhance capital efficiency.

Analysis Group Co-Authors Examine the Advancements in and Application of Health Economics and Outcomes Research to the Evaluation of Cell and Gene Therapies for...

BOSTON, July 22, 2025 /PRNewswire/ -- In a new article published in Value in Health, researchers from Analysis Group, a global leader in health economics...

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

Ignored and Undiagnosed: Sleep Apnea Threatens Women’s Cognitive Health

Alzheimer's disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing...

Halozyme to Report Second Quarter 2025 Financial and Operating Results

SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and...

uniQure to Announce Second Quarter 2025 Financial Results

uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET 
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET

Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology

New research paper highlights the unique structure and function of Nanoscope's synthetic opsin, supporting its potential in vision restoration DALLAS, July 22, 2025 /PRNewswire/...

DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass...

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers